# OnCo record nct06646276 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06646276/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06646276", "NCT06646276" ;
  schema:name "A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)"@en ;
  schema:alternateName "TIGOS"@en ;
  schema:description "A phase 3 trial testing Atigotatug in non-small-cell lung cancer, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06646276/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06646276> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-02-25" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/atigotatug/> ;
  onco:companies <https://onco.cc/companies/bms/> .